Rh five-antigen-matched transfusions associated with lower alloimmunization in patients needing repeated RBC transfusions
A randomized controlled trial investigated Rh five-antigen (D, C, c, E, e)–matched transfusions versus conventional antigen matching in patients requiring multiple red blood cell transfusions. The primary outcome was the incidence of RBC alloantibody formation. The study found a significantly lower incidence of alloantibody formation in the Rh five-antigen–matched group, though absolute numbers, effect sizes, and confidence intervals were not reported. Multivariable analyses were performed to adjust for potential confounders.
Secondary outcomes also favored the intervention. The Rh five-antigen–matched group had fewer transfusion-related adverse reactions, reduced RBC utilization, longer transfusion intervals, and shorter length of hospital stay. The direction of these associations was consistent, but specific numerical data for these outcomes were not provided in the abstract. Safety and tolerability details, including adverse events and discontinuations, were not reported.
Key limitations include the lack of reported sample size, follow-up duration, and specific numerical results for all outcomes. The funding source and potential conflicts of interest were also not reported. The abstract appropriately frames the findings as associations rather than proven causal effects. The authors note the long-term clinical value and cost-effectiveness should be further explored in multicenter studies.
For practice, this strategy represents a viable transfusion management approach for patients at high immunological risk. However, clinicians should interpret these preliminary findings with caution due to the absence of critical numerical data needed to fully assess the magnitude of benefit. Further research is needed to confirm these associations and establish practical implementation guidelines.